Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis

International Journal of Immunopathology and Pharmacology

Volumn 27, Issue 1, 2014, Pages 25-35

  Tzanno Martins, C ^a   Biavo, B M M ^a   Ferreira Filho, O ^a   Ribeiro Jr , E ^a   Joao Luiz M V S ^b   Degaspari, S ^b   Scavone, Cristoforo ^b   Kawamoto, E ^b  

^a Center of Study for Social and Health Humaniztion   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Efficacy; Generic equivalent; Phosphate binder; Safety; Sevelamer

Indexed keywords

BICARBONATE; C REACTIVE PROTEIN; CALCIUM; GENERIC DRUG; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHORUS; SEVELAMER; TUMOR NECROSIS FACTOR ALPHA; CHELATING AGENT; CHOLESTEROL; CYTOKINE; POLYAMINE; PHOSPHATE BINDING AGENT;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BICARBONATE BLOOD LEVEL; BLOOD PH; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EPIGASTRIC PAIN; FEMALE; FLATULENCE; HEARTBURN; HEMODIALYSIS; HUMAN; MALE; MEDICATION COMPLIANCE; NAUSEA; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION; XEROSTOMIA; BLOOD; CHRONIC KIDNEY FAILURE; CONTROLLED CLINICAL TRIAL; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME; HEADACHE; INCIDENCE; LOW FLUX HEMODIALYSIS; PH; SINGLE BLIND PROCEDURE;

C-REACTIVE PROTEIN; CHELATING AGENTS; CHOLESTEROL; CYTOKINES; DRUGS, GENERIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHORUS; POLYAMINES; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900529716     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201402700105     Document Type: Article

References (24)

1. Instituto Nacional de Alimentação e Nutrição. Pesquisa Nacional sobre Saúde e Nutrição - perfil de crescimento da população brasileira de 0 a 25 anos. Brasilia, INAN 1990.
2. Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 2000; 19:303-17.
3. Block GA, Hulbert-Shearon TE, levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:607-17.
4. Raggi P. Detection and quantification of cardiovascular calcifications with electron beam tomography to estimate risk in hemodialysis patients. Clin Nephrol 2000; 54:325-33.
5. Stenvinkel P. Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transplantation 2002; 17:33-38. (Pubitemid 34918877)
6. Haghdoost S, Maruyama Y, Pecoits-Filho R. Elevated serum 8- oxo-dG in hemodialysis patients: a marker of systemic inflammation? Antioxid Redox Signal 2006; 8:2169-73. (Pubitemid 46489640)
7. Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int 2004; 65:2371-79. (Pubitemid 38670023)
8. Sun PP, Perianayagam MC, Jaber BL. Sevelamer Hydrocloride use and circulation endotoxin in hemodialysis patients: A pilot cross-sectional study. J Renal Nutr 2009; 19(5):432-38.
9. Evenepoel P, Meijers BKI, Bammens BRM, Verbeke K. Uremic toxins originating from colonic microbial metabolism. Kidney Int 2009; 76(S):12-19.
10. Schepers E, Glorieux G, Vanholder R. The gut: The forgotten Organ in Uremia? Blood Purif 2010; 29(2):130-36.
11. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999; 55:299-307. (Pubitemid 29004263)
12. Chertow GM, Burke S, Dillon M, Slatopolsky E. for the Rena Gel Study group. Long-term effects of sevelamer hydrochloride on the calciumxphosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999; 14:2907-14.
13. Perianayagam MC, Jaber, BL. Endotoxin-binding affinity of sevelamer hydrochloride. Am J Nephrol 2008; 28(5):802-7.
14. De Santo NG, Frangiosa A, Anastasio P, et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 2006; 19(S):S108-14.
15. Almirall J, Lopez T, Vallve M, Ruiz A, Llibre J, Betriuc A. Safety and efficacy of Sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients. Nephron Clin Pract 2004; 97:c17-c22. (Pubitemid 38721044)
16. Casa Civil da República Federativa do Brasil. Law 9787. Available at: http://www.planalto.gov.br/cciv-il-03/leis/l9787.htm
17. David S, Merscher S, Schmidt Guertler H, Kielstein JT, Kirchhoff T, Meier M. A bitter pill to swallow. Clin Nephrol 2009; 72(4):319-21.
18. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149(5):820-25. (Pubitemid 40718876)
19. Stinguen AE, Gonçalves SM, Bucharles S, Branco FS, Gruber B, Hauser AB, Pecoits-Filho R. Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia. Blood Purif 2010; 29(4):352-56.
20. Lexicomp. Sevelamer: drug information. Available at: http://online.lexi. com/lco/action/doc/retrieve/docid/patch-f/7663#f-adverse-reactions
21. Braunlin W, Zhorov E, Guo A, et al. Bile acid binding to sevelamer hydrochloride. Kidney Int 2002; 62:611-19. (Pubitemid 34779775)
22. Cohen G, Hörl W H. Immune Dysfunction in Uremia. Toxins 2012, 4, 962-990; doi:10.3390/toxins4110962
23. Stenvinkel P. Inflammation in end-stage renal disease: The hidden enemy. Nephrol 2006; 11:36-41.
24. George SJ. WNT pathway - a new role in regulation of inflammation. Aterioscler Thromb Vasc Biol 2008; 28:400-402. Nível Superior Tecnológico